Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019

被引:1
|
作者
Gorczyca-Glowacka, Iwona [1 ,2 ]
Bielecka, Bernadetta [2 ]
Walek, Pawel [1 ,2 ]
Chrapek, Magdalena [3 ]
Ciba-Stemplewska, Agnieszka [4 ]
Jelonek, Olga [1 ,2 ]
Kot, Anna [2 ]
Czyzyk, Anna [1 ]
Pioro, Maciej [1 ]
Major, Agnieszka [1 ,2 ]
Wozakowska-Kaplon, Beata [1 ,2 ]
机构
[1] Jan Kochanowski Univ, Coll Med, PL-25369 Kielce, Poland
[2] Swietokrzyskie Cardiol Ctr, Clin Cardiol & Electrotherapy 1, PL-25736 Kielce, Poland
[3] Jan Kochanowski Univ, Fac Nat Sci, PL-25369 Kielce, Poland
[4] Integrated Prov Hosp, Dept Internal Med, PL-25736 Kielce, Poland
关键词
atrial fibrillation; non-vitamin K antagonist oral anticoagulants; oral anticoagulants; vitamin K antagonists; STROKE PREVENTION; WARFARIN; THROMBOEMBOLISM; IMPACT; RISK;
D O I
10.3390/ijerph19095584
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: In the recent years, antithrombotic prophylaxis in patients with atrial fibrillation (AF) has changed significantly. The main aim of this study is to assess the temporal trends of antithrombotic therapy and identify factors predisposing oral anticoagulant (OAC) use in stroke prevention in AF patients. Methods: The present study is a retrospective, observational, single-center study, which includes consecutively hospitalized patients in the reference cardiology center from January 2004 to December 2019. Results: A total of 9656 patients (43.7% female, mean age 71.2 years) with AF between 2004-2019 are included. Among the total study population, in most of the patients (81.1%), OAC therapy was used, antiplatelet (APT) therapy was prescribed for 13.5% patients, heparins for 2.1% patients and 3.3% of patients did not receive any stroke prevention. OAC prescription significantly increased from 61.6% in 2004 to 97.4% in 2019. The independent predictors of OAC prescription were: the period of hospitalization, non-paroxysmal AF, age, hypertension, diabetes mellitus, previous thromboembolism, hospitalization due to electrical cardioversion, ablation or AF without any procedures. Conclusions: In hospitalized patients with AF, during sixteen years of the study period, a significant increase in OAC use and a decrease in APT use were noted. Factors other than these included in the CHA(2)DS(2)-VASc score were independent predictors of OAC use.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Oral anticoagulant therapy for patients with atrial fibrillation - an update
    Hylek, Elaine M.
    [J]. THROMBOSIS RESEARCH, 2008, 123 : S46 - S49
  • [22] Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation
    Quesada, Carlos J. Gonzalez
    Giugliano, Robert P.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (01) : 129 - 138
  • [23] Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer
    Olesen, Kevin Kris Warnakula
    Wheeler, Matt
    Eikelboom, John W.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 194 - 196
  • [24] Personalizing oral anticoagulant treatment in patients with atrial fibrillation
    Capranzano, Piera
    Micciche, Eligio
    D'Urso, Lucia
    Privitera, Fiorella
    Tamburino, Corrado
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (08) : 959 - 973
  • [25] Oral Anticoagulant Discontinuation in Patients With Nonvalvular Atrial Fibrillation
    Kachroo, Sumesh
    Hamilton, Melissa
    Liu, Xianchen
    Pan, Xianying
    Brixner, Diana
    Marrouche, Nassir
    Biskupiak, Joseph
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (01): : E1 - E8
  • [26] Temporal trends in anticoagulant prescribing in patients with mild-to-moderate atrial fibrillation related stroke
    Hayden, D.
    Akijian, L.
    Hannon, N.
    Callaly, E.
    Ni Chroinin, D.
    Sheehan, O.
    Horgan, G.
    Fallon, E.
    Kyne, L.
    O'Rourke, K.
    Dolan, E.
    Williams, D.
    Murphy, S.
    Kelly, P. J.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 265 - 265
  • [27] Tailored oral anticoagulant prescription in patients with atrial fibrillation: Use and misuse of clinical risk prediction scores
    Proietti, Marco
    Vitolo, Marco
    Boriani, Giuseppe
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (07) : 726 - 728
  • [28] Mental health and anticoagulant prescription in atrial fibrillation
    Calvert, Peter
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    [J]. EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (03) : 235 - 237
  • [29] Temporal Trends in the Incidence, Prevalence, and Survival of Patients With Atrial Fibrillation From 2004 to 2016
    Williams, Brent A.
    Honushefsky, Ashley M.
    Berger, Peter B.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (11): : 1961 - 1965
  • [30] Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019
    Ajabnoor, Alyaa M.
    Parisi, Rosa
    Zghebi, Salwa S.
    Ashcroft, Darren M.
    Faivre-Finn, Corinne
    Morris, Charlotte
    Mamas, Mamas A.
    Kontopantelis, Evangelos
    [J]. CANCER, 2024, 130 (08) : 1316 - 1329